Clinical Trial

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Single-Center, Phase 1 study to assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-15; most recent amendment 2026-01-26.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-10-20
Trial Details
NCT Number NCT06978244
Lead Sponsor Bausch & Lomb Incorporated
Conditions Ocular Pain
Enrollment 24 participants
Start Date 2025-07-29
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-01-27